This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Noble, S.I.R. Articles by Finlay, I.G. Search for Related Content PubMed PubMed Citation Articles by Noble, S.I.R. Articles by Finlay, I.G. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Cancer Palliative Care Social Bookmarking                         What's this?

The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients

Palliative Medicine, Cardiff University, Cardiff and Royal Gwent Hospital, Newport, simon.noble{at}gwent.wales.nhs.uk

K. Hood

South East Wales Trials Unit Centre for Health Sciences, Cardiff University, Cardiff

I.G. Finlay

Palliative Medicine, Cardiff University, Cardiff and University of Groningen, Groningen

The advantages of low-molecular weight heparin (LMWH) over warfarin, in the treatment of cancer associated venous thromboembolism (VTE) are well reported. However the studies supporting LMWH include few patients representative of the palliative care population. Although LMWH has advantages over warfarin it is still unclear, within the palliative care environment, how long anticoagulation should be continued, what dose of LMWH should be used and whether palliative care patients experience different complication rates such as bleeding, heparin-induced thrombocytopenia and osteoporosis.

We report a case series of 62 patients with advanced malignancy and VTE treated with long-term LMWH according to either the CLOT (full dose) or Monreal (reduced dose) regime. Seventy-four percent of patients self-administered LMWH, whereas 24% had it given by a carer and 2% by the district nurse. LMWH was given for median duration of 97 days; the most common reason for discontinuation of therapy being admission to die or commencement of the care pathway (n = 50, 81%). A further 11% (n = 7) stopped after 6 months of treatment. Of these 3 (43%) developed clinical symptomatic recurrence of VTE. The overall minor bleeding rate was 8.1% (95% confidence interval 3.5—17.5%), and this was not associated with NSAID or steroid use. No major bleeding events were observed. No patients developed evidence of heparin-induced thrombocytopenia or osteoporosis.

Long-term LMWH appears effective in treatment of VTE in the palliative care population with advanced cancer. A randomised control trial is required to identify the best dose required to ensure optimum efficacy and safety. Palliative Medicine 2007; 21 : 473—476

Key Words: venous thromboembolism • cancer • hospice • palliative • LMWH

Palliative Medicine, Vol. 21, No. 6, 473-476 (2007)
DOI: 10.1177/0269216307080816


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Soto-Cardenas, G Pelayo-Garcia, A Rodriguez-Camacho, E Segura-Fernandez, A Mogollo-Galvan, and J. Giron-Gonzalez Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice Palliative Medicine, December 1, 2008; 22(8): 965 - 968. [Abstract] [PDF]

				A. Falanga, A. Y. Y. Lee, M. B. Streiff, and G. H. Lyman Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 258 - 268. [Abstract] [Full Text] [PDF]

				S Noble The challenges of managing cancer related venous thromboembolism in the palliative care setting Postgrad. Med. J., November 1, 2007; 83(985): 671 - 674. [Abstract] [Full Text] [PDF]